HOME >> MEDICINE >> NEWS
New method of administering anti-cancer drug may be more effective, safer

CHAPEL HILL -- A novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion may be more effective and safer than the method currently used, new study findings indicate.

The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.

The findings were presented at the 2005 annual meeting of the American Society of Clinical Oncology, held May 13 through 17 in Orlando, Fla. The drug busulfan is used in leukemia patients to kill cancerous cells before bone-marrow transplant. Currently, it is administered in intermittent intravenous doses, typically via two-hour infusions of the drug every six hours. Previous studies have reported that frequent dose adjustments are needed to maintain the desired level of drug in patients and that metabolism of the drug varies from patient to patient.

"The new continuous-infusion method achieved more predictable levels of the drug than does the usual delivery method," said Dr. Thomas C. Shea, professor of medicine at UNC, director of the Bone Marrow Transplant Program at the UNC Health Care System and a member of the UNC Lineberger Comprehensive Cancer Center.

"In the relatively small number of patients tested with continuous infusion, there didn't appear to be a change in concentration or clearance of the drug during the 90-hour infusion period."

In 12 patients scheduled for bone marrow transplants, UNC researchers administered a single busulfan test dose of 0.8 mg/kg adjusted body weight over two hours. Blood concentrations of the drug were measured every two hours for eight hours following that test dose.

Then researchers administered busulfan by the novel method - patient
'"/>

Contact: Leslie H. Lang
llang@med.unc.edu
919-843-9687
University of North Carolina School of Medicine
18-May-2005


Page: 1 2

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. U of M researchers discover new method to combat HIV
3. New prevention, treatment methods for patients with painful bowel inflammation
4. Scientists develop method to track immune system enzyme in live animals
5. VA should revise its methods for evaluating and rating PTSD in veterans
6. Northwestern chemists develop new method for synthesizing anti-cancer flavonoids
7. Scientists develop method to remove prion infectivity from scrapie-infected blood
8. PhD researcher develops inexpensive, sustainable production method in just 2 years
9. Researchers develop novel method for treatment of sickle cell disease
10. Developing better methods of blinding doctors and patients in clinical trials
11. Cancer survival compromised by poor staging methods

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New method administering anti cancer drug may more effective safer

(Date:7/25/2014)... 25, 2014 Bedros Keuilian has been ... in the country, and is considered the industry’s leading ... on his coaching website, RenegadeMarketing.com, he explains why information ... a good personal trainer. , “I’ve been really privileged ... leaders in the fitness industry and I’ve helped many ...
(Date:7/25/2014)... for Medical Oncology (ESMO), the leading pan-European association ... the proposed EU General Data Protection Regulation [1] ... significant burden to both doctors and cancer patients. ... stipulates ,explicit and specific patient consent, meaning that ... time research is planned in order to consult ...
(Date:7/25/2014)... Seattle, Wa (PRWEB) July 25, 2014 ... More Pdf review recently updated by Vkool.com, ... teach people how to treat some common ...     External hemorrhoids and internal hemorrhoids , ... after pregnancy with hemorrhoids ,     Very ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... York, NY (PRWEB) July 25, 2014 ... innovator in health care quality, has been appointed senior ... effective July 21, 2014. In his new role, he ... initiatives. , Dr. Ting has successfully led quality initiatives ... levels. Nationally, he led teams for the Door-to-Balloon Alliance, ...
Breaking Medicine News(10 mins):Health News:Fitness Marketing Expert Bedros Keuilian’s New Post Shares Why People Still Need Personal Trainers in the Age of Google 2Health News:Fitness Marketing Expert Bedros Keuilian’s New Post Shares Why People Still Need Personal Trainers in the Age of Google 3Health News:Is Europe putting cancer research at risk? 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3
(Date:7/25/2014)... 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... update and report second quarter 2014 financial results before ... 1, 2014. That same day, Arena will host a ... (5:30 a.m. Pacific Time). The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
Cached News: